Jazz Pharmaceuticals has been granted a patent for a novel liposome formulation designed to encapsulate sparingly soluble drugs, enhancing their delivery for life-threatening diseases. The method involves remote loading, allowing for high drug-to-lipid ratios and effective retention without the need for solubilizing agents. GlobalData’s report on Jazz Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals's grant share as of July 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Liposome compositions for sparingly soluble drug delivery
The granted patent US12070471B2 describes a novel pharmaceutical formulation that utilizes liposomes to encapsulate a sparingly water-soluble agent. The formulation consists of a lipid fraction primarily composed of sphingomyelin, which forms the liposome, and an internal aqueous medium containing a solid precipitate of a salt of the sparingly water-soluble agent, characterized by a water solubility of less than approximately 2 mg/mL. Notably, the liposome is designed to be free of any solubilizing agents for the encapsulated agent. The patent outlines various types of liposomes that can be employed, including multilamellar vesicles (MLV), large unilamellar vesicles (LUV), and small unilamellar vesicles (SUV), with diameters ranging from about 40 nm to 150 nm. Additionally, the lipid fraction may include cholesterol and PEG-lipid conjugates, with specific molar percentages detailed in the claims.
The formulation is further characterized by the presence of a sparingly water-soluble amphipathic weak base or weak acid, with defined properties regarding their octanol-water distribution coefficients and pKa values. The patent also specifies that the sparingly water-soluble agent can be present in a unit dosage format within the internal aqueous medium, and it outlines a specific ratio of the agent to lipid in the liposomes. Furthermore, the patent claims a lyophilized version of the formulation and describes a method for treating disease states in subjects by administering a therapeutically effective amount of the described pharmaceutical formulation. This innovative approach aims to enhance the delivery and efficacy of sparingly water-soluble agents in therapeutic applications.
To know more about GlobalData’s detailed insights on Jazz Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
